Arthur A. Levin, CEO of Avitedity Biociences, Inc. (Nasdaq :), he recently sold 1872 shares of the company. The shares were sold at a weighted average price of $ 28.60, which is a total of approximately $ 53,536. According to Investingpro According to the data, the RNA shares have increased by almost 197% during the last year, with shares currently traded just above the estimated fair value. This transaction was part of the “Selling” arrangement to fulfill tax liabilities on deduction in connection with the award of limited shareholding units (RSU) on January 20, 2025. The shares were sold on January 21, 2025, as ordered by Aviedity’s capital incentive plans. After this transaction, Levin directly holds 12,958 shares, with an additional 131,372 shares that indirectly holds through the family trust. With analysts who set targeted prices ranging from $ 51 to $ 96, Investingpro Subscribers can approach comprehensive insider trading patterns and 10 additional exclusive opposite containers for RNA shares.
In other recent news, Avitedity biosciences reported revenue in the third quarter of 2024. Of the $ 175.4 million, a slightly excessive consensus of Factset. The company has adapted its guidelines on a year-round revenue for the Fiscal Year 2024. A range of $ 665-685 million. HC Wainwright and Goldman Sachs started covering on Avitedity Biociences with a Kupi rating, setting targeted prices of $ 72.00 or $ 59.00.
Analysts from RBC Capital Markets also launched a report on Avitedity Biociences with an Outperform assessment, setting a target price of $ 67.00. Furthermore, Avitedity Biociences has expanded its sales forces for 150 representatives, with the aim of expanding their reach among the doctors of primary health care. The company has set a goal for sales for its cure for bipolar depression and a major depressing disorder, Caplyta, projecting over $ 5 billion sales in the next decade.
The US Food and Medicines Agency has abolished partially clinical holding of Avited’s drug candidate, Del-dessued, allowing the Phase 3 of Harbor Tests. Avitedity biosciences also announced a public offer of ordinary shares in the amount of $ 250 million, operated by Leerink Partners and TD Cowen to support their clinical programs and improve research and development.
Finally, Goldman Sachs and TD Cowen repeated their rating to buy Aviation shares, emphasizing the potential of his Del-Bax and Del-Desiran drugs, with a top sale of $ 2.7 or $ 4.0 billion. These are recent achievements in Avitedity Biociences.
This article was generated with the support of AI and was examined by the editor. See our T&C for more information.
